LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Kawakami, Fumitaka ^a   Yabata, Takatoshi ^a   Ohta, Etsuro ^a   Maekawa, Tatsunori ^a   Shimada, Naoki ^a   Suzuki, Minori ^a   Maruyama, Hiroko ^a   Ichikawa, Takafumi ^a   Obata, Fumiya ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCINE; ISOLEUCINE; LEUCINE RICH REPEAT KINASE 2; SERINE; TAU PROTEIN; THREONINE; TUBULIN; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CELL ASSAY; CELL TRANSPORT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; HUMAN; HUMAN CELL; MEDIATOR RELEASE; MICROTUBULE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NERVE FIBER GROWTH; PARKINSON DISEASE; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; GENE SILENCING; METABOLISM; NEURITE; PHOSPHORYLATION; PROTEIN BINDING; SWINE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HUMANS; MODELS, BIOLOGICAL; NEURITES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; SUS SCROFA; TAU PROTEINS; TUBULIN;

EID: 84856404449     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030834     Document Type: Article

References (42)

1. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW, (1975) A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA 72: 1858-1862.
2. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA, (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3: 519-526.
3. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I, (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118: 53-69.
4. Avila J, Lucas JJ, Perez M, Hernandez F, (2004) Role of tau protein in both physiological and pathological conditions. Physiol Rev 84: 361-384.
5. Dickson DW, (2009) Neuropathology of non-Alzheimer degenerative disorders. Int J Clin Exp Pathol 3: 1-23.
6. Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600.
7. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607.
8. Cookson MR, (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11: 791-797.
9. Biskup S, West AB, (2009) Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta 1792: 625-633.
10. Dächsel JC, Farrer MJ, (2010) LRRK2 and Parkinson disease. Arch Neurol 67: 542-547.
11. Maekawa T, Kubo M, Yokoyama I, Ohta E, Obata F, (2010) Age-dependent and cell-population-restricted LRRK2 expression in normal mouse spleen. Biochem Biophys Res Commun 392: 431-435.
12. Kubo M, Kamiya Y, Nagashima R, Maekawa T, Eshima K, et al. (2010) LRRK2 is expressed in B-2 but not in B-1 B cells, and downregulated by cellular activation. J Neuroimmunol 229: 123-128.
13. Cookson MR, Dauer W, Dawson T, Fon EA, Guo M, et al. (2007) The roles of kinases in familial Parkinson's disease. J Neurosci 27: 11865-11868.
14. Gillardon F, (2009) Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration?. J Neurochem 110: 1514-1522.
15. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, et al. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52: 587-593.
16. Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT, (2008) Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 105: 1048-1056.
17. Chan D, Citro A, Cordy JM, Shen GC, Wolozin B, (2011) Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J Biol Chem 286: 16140-16149.
18. Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, et al. (2009) Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29: 13971-13980.
19. Ramonet D, Daher JP, Lin BM, Stafa K, Kim J, et al. (2011) Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 6: e18568.
20. Li Y, Liu W, Oo TF, Wang L, Tang Y, et al. (2009) Mutant LRRK2 (R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12: 826-828.
21. Melrose HL, Dächsel JC, Behrouz B, Lincoln SJ, Yue M, et al. (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 40: 503-517.
22. Rajput A, Dickson DW, Robinson CA, Ross OA, Dächsel JC, et al. (2006) Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67: 1506-1508.
23. Lin CH, Tsai PI, Wu RM, Chien CT, (2010) LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK-3β. J Neurosci 30: 13138-13149.
24. Zach S, Felk S, Gillardon F, (2010) Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity. PLoS ONE 5: e13191.
25. Ohta E, Katayama Y, Kawakami F, Yamamoto M, Tajima K, et al. (2009) I(2020)T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular degradation rate than the wild-type molecule. Biochem Biophys Res Commun 390: 710-715.
26. Ohta E, Kubo M, Obata F, (2010) Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis. Biochem Biophys Res Commun 391: 242-247.
27. Ohta E, Kawakami F, Kubo M, Obata F, (2011) LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: Impairment of the kinase activity by Parkinson's disease-associated mutations. FEBS Lett 585: 2165-2170.
28. Kawakami F, Suzuki K, Ohtsuki K, (2008) A novel consensus phosphorylation motif in sulfatide- and cholesterol-3-sulfate-binding protein substrates for CK1 in vitro. Biol Pharm Bull 31: 193-200.
29. Kawakami F, Yamaguchi A, Suzuki K, Yamamoto T, Ohtsuki K, (2008) Biochemical characterization of phospholipids, sulfatide and heparin as potent stimulators for autophosphorylation of GSK-3β and the GSK-3β-mediated phosphorylation of myelin basic protein in vitro. J Biochem 143: 359-367.
30. Maldonado H, Ortiz-Riaño E, Krause B, Barriga A, Medina F, et al. (2008) Microtubule proteins and their post-translational forms in the cerebrospinal fluid of patients with paraparesis associated with HTLV-I infection and in SH-SY5Y cells: an in vitro model of HTLV-I-induced disease. Biol Res 41: 239-259.
31. Maldonado H, Ramírez E, Utreras E, Pando ME, Kettlun AM, et al. (2011) Inhibition of cyclin-dependent kinase 5 but not of glycogen synthase kinase 3-β prevents neurite retraction and tau hyperphosphorylation caused by secretable products of human T-cell leukemia virus type I-infected lymphocytes. J Neurosci Res 89: 1489-1498.
32. Dächsel JC, Taylor JP, Mok SS, Ross OA, Hinkle KM, et al. (2007) Identification of potential protein interactors of Lrrk2. Parkinsonism Relat Disord 13: 382-385.
33. Meixner A, Boldt K, Van Troys M, Askenazi M, Gloeckner CJ, et al. (2011) A QUICK screen for Lrrk2 interaction partners-leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. Mol Cell Proteomics 10: M110.001172.
34. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I, (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7: 656-664.
35. Deas E, Dunn L, (2010) Unraveling LRRK2 pathogenesis: common pathways for complex genes? J Neurosci 30: 1577-1579.
36. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, et al. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405: 307-317.
37. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, et al. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 27: 2432-2443.
38. Gloeckner, CJ, Schumacher A, Boldt K, Ueffing M, (2009) The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem 109: 959-968.
39. Iaccarino C, Crosio C, Vitale C, Sanna G, Carrì MT, et al. (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 16: 1319-1326.
40. Webber PJ, West AB, (2009) LRRK2 in Parkinson's disease: function in cells and neurodegeneration. FEBS J 276: 6436-6444.
41. Miklossy J, Arai T, Guo JP, Klegeris A, Yu S, et al. (2006) LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropathol Exp Neurol 65: 953-963.
42. Miklossy J, Qing H, Guo JP, Yu S, Wszolek ZK, et al. (2007) Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. Acta Neuropathol 114: 243-254.